文献速递头痛与眩晕脑血管病

依瑞奈尤单抗预防偏头痛的血管安全性

Vascular safety of erenumab for migraine prevention.
PubMed 文献 · Neurology · 2019-12-18

该研究整合了4项双盲安慰剂对照研究及其开放标签扩展,评估依瑞奈尤单抗在偏头痛预防中的心血管、脑血管及外周血管安全性。结果显示,在12周双盲期内,依瑞奈尤单抗的血管不良事件发生率与安慰剂相似,且未随时间增加;独立委员会裁定4例心血管事件均发生在开放标签治疗期间。

要点

  • 双盲期内依瑞奈尤单抗的血管不良事件发生率与安慰剂相当。
  • 高血压不良事件率分别为安慰剂0.9%、70mg组0.8%、140mg组0.2%。
  • 独立裁定的4例心血管事件均发生于开放标签治疗阶段。

核心结论

  • 依瑞奈尤单抗预防偏头痛的血管安全性在12周内与安慰剂相当,且未随时间增加事件。

研究设计与样本

  • 整合4项双盲安慰剂对照研究及其开放标签扩展,纳入慢性或发作性偏头痛患者。

主要发现

  • 双盲期内安慰剂组1043例、依瑞奈尤单抗70mg组893例、140mg组507例每月皮下注射一次。
  • 高血压不良事件发生率:安慰剂0.9%、70mg组0.8%、140mg组0.2%。
  • 血管不良事件在双盲与开放标签治疗中相似,多存在混杂因素。
  • 独立委员会评审18例事件,裁定4例为心血管起源:2例死亡和2例血管事件。
  • 所有4例裁定事件均发生在开放标签依瑞奈尤单抗治疗期间。

关键数值与推荐

  • 双盲期内血管不良事件发生率在安慰剂与依瑞奈尤单抗组间相似,不受急性偏头痛特异性药物使用或基线血管危险因素影响。

临床怎么用

  • 对于偏头痛患者,依瑞奈尤单抗在12周内不增加血管不良事件风险,但长期安全性仍需进一步研究。

局限性

  • 开放标签扩展缺乏安慰剂对照,且事件裁定数量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the cardiovascular, cerebrovascular, and peripheral vascular safety of erenumab across migraine prevention studies. METHODS: Vascular adverse events (AEs) and blood pressure data were integrated across 4 double-blind, placebo-controlled studies of erenumab and their open-label extensions in patients with chronic or episodic migraine. Subgroup analyses were conducted by acute migraine-specific medication use and number of vascular risk factors at baseline. Standardized search terms were used to identify vascular AEs (cardiovascular, cerebrovascular, or peripheral). An independent committee adjudicated whether targeted events were vascular in origin. RESULTS: In placebo-controlled studies, 2,443 patients received placebo (n = 1,043), erenumab 70 mg (n = 893), or erenumab 140 mg (n = 507) subcutaneously once monthly. Regardless of acute migraine-specific medication use or vascular risk factors at baseline, AE incidence was similar across the placebo and erenumab treatment groups. Hypertension AEs were reported for 0.9% (placebo), 0.8% (erenumab 70 mg), and 0.2% (erenumab 140 mg) of patients. Vascular AEs, which were similar across double-blind and open-label treatment, generally were confounded, with plausible alternative etiologies. In 18 patients with events reviewed by the independent committee, 4 events were positively adjudicated as cardiovascular in origin: 2 deaths and 2 vascular events. All 4 positively adjudicated cardiovascular events occurred during open-label erenumab treatment. CONCLUSION: Selective blockade of the canonical calcitonin gene-related peptide receptor with erenumab for migraine prevention had a vascular safety profile comparable to that of placebo over 12 weeks, with no increased emergence of events over time. Further study of long-term safety of erenumab in patients with migraine is needed. CLINICALTRIALSGOV IDENTIFIERS: NCT02066415, NCT02456740, NCT01952574, NCT02483585, NCT02174861, and NCT01723514. CLASSIFICATION OF EVIDENCE: This analysis provides Class II evidence that for patients with migraine, erenumab does not increase the risk of vascular AEs.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Kudrow D, Pascual J, Winner PK, et al. Vascular safety of erenumab for migraine prevention. Neurology. 2019. PMID: 31852816. doi:10.1212/WNL.0000000000008743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。